MX2013010306A - Formulaciones de dispersion solida y metodos de uso de las mismas. - Google Patents

Formulaciones de dispersion solida y metodos de uso de las mismas.

Info

Publication number
MX2013010306A
MX2013010306A MX2013010306A MX2013010306A MX2013010306A MX 2013010306 A MX2013010306 A MX 2013010306A MX 2013010306 A MX2013010306 A MX 2013010306A MX 2013010306 A MX2013010306 A MX 2013010306A MX 2013010306 A MX2013010306 A MX 2013010306A
Authority
MX
Mexico
Prior art keywords
methods
solid dispersion
dispersion formulations
formulations
diphenylpropanoyl
Prior art date
Application number
MX2013010306A
Other languages
English (en)
Inventor
Mahesh V Padval
Jeff T Gautschi
Daniel T Smithey
Marshall D Crew
Abizer Harianawala
Original Assignee
Zalicus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zalicus Pharmaceuticals Ltd filed Critical Zalicus Pharmaceuticals Ltd
Publication of MX2013010306A publication Critical patent/MX2013010306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Mechanical Engineering (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones y métodos para incrementar la bio-disponibilidad de 1-(4-benzhidrilpiperazin-1-i1 )-3,3-difenilpropan-1-ona, 1-(3,3- difenilpropanoil)piperazina, o una sal de la misma. En particular, la formulación puede incluir uno o más polímeros de matriz farmacéuticamente aceptables para formar una dispersión sólida, v.gr., una dispersión secada por rocío o una extrusión fundida caliente.
MX2013010306A 2011-03-08 2012-03-07 Formulaciones de dispersion solida y metodos de uso de las mismas. MX2013010306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161450479P 2011-03-08 2011-03-08
US201161485405P 2011-05-12 2011-05-12
PCT/US2012/028088 WO2012122279A1 (en) 2011-03-08 2012-03-07 Solid dispersion formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2013010306A true MX2013010306A (es) 2013-12-09

Family

ID=46798550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010306A MX2013010306A (es) 2011-03-08 2012-03-07 Formulaciones de dispersion solida y metodos de uso de las mismas.

Country Status (10)

Country Link
US (1) US8591944B2 (es)
EP (1) EP2654726A4 (es)
JP (1) JP2014507424A (es)
KR (1) KR20140011366A (es)
CN (1) CN103491964A (es)
AU (1) AU2012225459A1 (es)
BR (1) BR112013022788A2 (es)
CA (1) CA2828610A1 (es)
MX (1) MX2013010306A (es)
WO (1) WO2012122279A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN03135A (es) * 2012-09-28 2015-10-02 Oncoethix Sa
KR102191562B1 (ko) 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
DE202012012130U1 (de) 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
US10016508B2 (en) 2013-06-03 2018-07-10 Shin-Etsu Chemical Co., Ltd. Composition for hot-melt extrusion and method for producing hot-melt extrusion product using same
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN106102744A (zh) * 2014-01-09 2016-11-09 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合物和方法
AU2015214502B2 (en) * 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
ES2907285T3 (es) * 2014-03-06 2022-04-22 Elanco Animal Health Incorporated Composiciones de grapiprant y procedimientos de uso de las mismas
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
KR101722564B1 (ko) * 2014-09-16 2017-04-03 강원대학교산학협력단 수-난용성 약물을 포함하는 고체분산체
US11089804B2 (en) 2014-12-11 2021-08-17 Shin-Etsu Chemical Co., Ltd. Oil-in-water type composition and food using same
EP3307246A1 (en) * 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107028931A (zh) 2016-02-04 2017-08-11 上海宣泰医药科技有限公司 一种紫杉醇药物组合物及其药物制剂、制备方法和用途
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
CN105816423B (zh) * 2016-03-16 2018-07-20 福建天泰医药科技有限公司 依达拉奉剂型
CN105997883A (zh) * 2016-05-06 2016-10-12 杭州容立医药科技有限公司 一种固体分散体及其制备方法和应用
CN105832672A (zh) * 2016-05-06 2016-08-10 杭州容立医药科技有限公司 一种固体分散体的制备方法和应用
JP7112333B2 (ja) * 2016-05-09 2022-08-03 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー 改善された薬物製剤
US10723807B2 (en) 2017-03-31 2020-07-28 Shin-Etsu Chemical Co., Ltd. Method for producing hydroxyalkyl alkyl cellulose
ES2886842T3 (es) * 2017-04-13 2021-12-21 Jean Paul Remon Composiciones a base de xanthohumol
MX2021001063A (es) * 2018-07-30 2021-04-12 Chugai Pharmaceutical Co Ltd Dispersion solida de derivado de hidantoina.
AU2020353381A1 (en) * 2019-09-23 2022-04-07 Bionomics Limited Therapeutic formulations and uses thereof
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051527A (es) 1964-07-31
GB1178623A (en) 1966-05-10 1970-01-21 Sandoz Ltd Phenothiazine Derivatives
CH497458A (de) 1967-04-19 1970-10-15 Sandoz Ag Verfahren zur Herstellung neuer Phenothiazin-Derivate
US4188485A (en) 1978-06-16 1980-02-12 G. D. Searle & Co. 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
US4411904A (en) 1981-05-29 1983-10-25 Warner-Lambert Company Diphenylpropanamines, compositions thereof and use thereof
US4766125A (en) 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
ES8308553A1 (es) 1982-06-17 1983-09-01 Ferrer Int "procedimiento de obtencion de nuevos derivados de piperazina".
JPS61155358A (ja) 1984-12-21 1986-07-15 Suntory Ltd ジアリール酪酸誘導体
FR2584723B1 (fr) 1985-07-09 1988-02-12 Adir Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US4782071A (en) 1986-11-03 1988-11-01 Warner-Lambert Company Tetrasubstituted urea cholinergic agents
US5386025A (en) 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5703071A (en) 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
TW205034B (es) 1990-09-13 1993-05-01 Pola Kasei Kogyo Kk
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
US5292726A (en) 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
CA2153979C (en) 1993-12-08 2003-10-21 Mark Hellberg Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US5623051A (en) 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5866574A (en) 1997-04-10 1999-02-02 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
SE9702564D0 (sv) 1997-07-02 1997-07-02 Astra Ab New compounds
AU8762798A (en) 1997-08-11 1999-03-01 Warner-Lambert Company Aniline derivatives as calcium channel blockers
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US6541479B1 (en) 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6951862B2 (en) 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US20060084660A1 (en) 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20040259866A1 (en) 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6943168B2 (en) 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20040266784A1 (en) 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
AU4329399A (en) 1998-07-30 2000-02-21 Warner-Lambert Company Tyrosine-derived compounds as calcium channel antagonists
AU4329499A (en) 1998-07-30 2000-02-21 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6267945B1 (en) 1998-12-18 2001-07-31 Neuromed Technologies, Inc. Farnesol-related calcium channel blockers
US6310058B1 (en) 1999-05-27 2001-10-30 University Of Notre Dame Du Lac Antimycobacterial agents
AU5568300A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyridine derivative
MXPA02006324A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0004056D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BR0307333A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20030199523A1 (en) 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
US20040005359A1 (en) 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
CA2496441C (en) 2002-08-12 2010-03-16 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
EP1581558A2 (en) 2003-01-07 2005-10-05 Neuromed Technologies, Inc. Fluorescence based t-type channel assay
EP1633343A1 (en) 2003-05-30 2006-03-15 Neuromed Technologies, Inc. 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
EP1675548A4 (en) * 2003-09-25 2008-08-13 Activbiotics Inc RIFALAZIL FORMULATIONS
US20050227999A1 (en) 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
DE602005010074D1 (de) 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
EP1765283A4 (en) * 2004-06-08 2012-11-28 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
WO2006105670A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
EP1976841A4 (en) 2005-12-19 2010-07-28 Neuromed Pharmaceuticals Ltd HETEROCYCLIC AMIDDERIVES AS CALCIUM CHANNEL BLOCKERS
US20070248668A1 (en) 2006-04-06 2007-10-25 Michaelis Arthur F Pharmaceutical compositions and uses thereof
WO2007118323A1 (en) 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
EP2019676A2 (en) 2006-05-11 2009-02-04 Neuromed Pharmaceuticals, Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US20100029681A1 (en) 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
EP2061780A4 (en) 2006-09-14 2010-12-22 Zalicus Pharmaceuticals Ltd DIARYLE PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS
EP2074105A4 (en) 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
US20090012010A1 (en) 2007-05-18 2009-01-08 Neuromed Phramaceuticals Ltd. Amino acid derivatives as calcium channel blockers
US20090270394A1 (en) 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
WO2009132452A1 (en) 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Diaryl-cyclylalkyl derivatives as calcium channel blockers
CA2722706A1 (en) 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof

Also Published As

Publication number Publication date
CN103491964A (zh) 2014-01-01
BR112013022788A2 (pt) 2016-12-06
AU2012225459A1 (en) 2013-10-10
JP2014507424A (ja) 2014-03-27
US8591944B2 (en) 2013-11-26
CA2828610A1 (en) 2012-09-13
EP2654726A1 (en) 2013-10-30
KR20140011366A (ko) 2014-01-28
EP2654726A4 (en) 2013-10-30
WO2012122279A1 (en) 2012-09-13
US20130035345A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
MX2013010306A (es) Formulaciones de dispersion solida y metodos de uso de las mismas.
HK1259355A1 (zh) 作為btk激酶抑制劑的2，3-二氫異吲哚-1-酮衍生物、以及含有所述衍生物的藥物組合物
EP3181559A4 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
EP3216448B8 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
MX2014014711A (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar).
MX2014014710A (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar).
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
EP2657231A4 (en) SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING AND USING SAME
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
HK1181389A1 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2013150529A3 (en) Indole, indoline derivatives, compositions comprising them and uses thereof
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
IL211713A (en) History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
IN2014DN09347A (es)
IL202235A (en) Amides and thioamides of 2-phenyl-ethyl-amino-acid, their history and their pharmaceutical preparations
WO2013190508A3 (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
WO2014062838A3 (en) Pkm2 modulators and methods for their use
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal